Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NPS Pharmaceuticals, a developer of therapeutics for rare gastrointestinal and endocrine disorders with high-unmet medical needs, has reported total revenues of $27.21m for the second quarter ended 30 June 2011, compared to $24.02m for the same period in 2010.
Subscribe to our email newsletter
NPS Pharma has posted net loss of $6.13m, compared to $6.3m for the same period in the prior year.
The company’s operating income was $4.04m for the second quarter ended 30 June 2011, against $4.03m for the same period in 2010.
NPS Pharma president and CEO Francois Nader said their clinical, regulatory and technical operations teams are on track with the execution of the two Phase 3 registration programs for Gattex and NPSP558.
"We expect to report results from the Phase 3 Replace clinical study of NPSP558 in patients with hypoparathyroidism in the fourth quarter and pursue US registration of the drug if study results are positive," Nader said.